|
|
|
|
| |
|
|
| Spósito,A.C.; Vinagre,C.G.; Pandullo,F.L; Mies,S.; Raia,S.; Ramires,J.A.F.. |
| Total serum lipids, as well as apolipoproteins A-I (apo A-I) and B (apo B), were determined in 74 patients with chronic liver failure without cholestasis and in 82 normal subjects. The VLDL, LDL and HDL lipid fractions were reduced in the liver failure group by 36%, 24% and 46%, respectively (P<0.001). Apolipoproteins A-I and B were also reduced by 26% and 25%, respectively (P<0.001). However, the reduction of HDL cholesterol (HDLc) was more pronounced than that of apo A-I and the HDLc:apo A-I ratio was significantly lower in the liver failure group. After separating these patients into groups with plasma albumin lower than 3.0, between 3.0 and 3.5, and higher than 3.5 g/dl, the HDLc:apo A-I ratio was proportional to plasma albumin, but the... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Chronic liver disease; Liver failure; Apolipoprotein A; Apolipoprotein B; LCAT; HDL cholesterol; VLDL cholesterol; Lipid metabolism. |
| Ano: 1997 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X1997001100004 |
| |
|
|
| Murad,H.A.; Gazzaz,Z.J.; Ali,S.S.; Ibraheem,M.S.. |
| Minimal hepatic encephalopathy is more common than the acute syndrome. Losartan, the first angiotensin-II receptor blocker (ARB), and candesartan, another widely-used ARB, have protected against developing fibrogenesis, but there is no clear data about their curative antifibrotic effects. The current study was designed to examine their effects in an already-established model of hepatic fibrosis and also their effects on the associated motor dysfunction. Low-grade chronic liver failure (CLF) was induced in 3-month old Sprague-Dawley male rats using thioacetamide (TAA, 50 mg·kg−1·day−1) intraperitoneally for 2 weeks. The TAA-CLF rats were randomly divided into five groups (n=8) treated orally for 14 days (mg·kg−1·day−1) as follows: TAA (distilled water),... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Candesartan; Hepatic fibrosis; Liver failure; Losartan; Motor dysfunction; Thioacetamide. |
| Ano: 2017 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017001100611 |
| |
|
|
| Wei,Xinhuan; Yu,Haibin; Zhao,Peng; Xie,Li; Li,Li; Zhang,Jing. |
| Regucalcin is a soluble protein that is principally expressed in hepatocytes. Studies of regucalcin have mainly been conducted in animals due to a lack of commercially available kits. We aimed to develop an enzyme-linked immunosorbent assay (ELISA) to quantify serum regucalcin in patients with hepatitis B virus (HBV)-related disease. High-titer monoclonal antibodies and a polyclonal antibody to regucalcin were produced, a double-antibody sandwich ELISA method was established, and serum regucalcin was determined in 47 chronic hepatitis B (CHB) patients, 91 HBV-related acute-on-chronic liver failure (HBV-ACLF) patients, and 33 healthy controls. The ELISA demonstrated an appropriate linear range, and high levels of reproducibility, sensitivity, specificity,... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Regucalcin; Liver injury; Chronic hepatitis B infection; ELISA; Liver failure. |
| Ano: 2019 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2019001000605 |
| |
|
| |
|
|
|
